导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.32% | 4102/4773 |
| 近一周 | -2.23% | 4183/5467 |
| 近一月 | -5.59% | 2492/5421 |
| 近一季 | 3.44% | 487/5238 |
| 近半年 | -13.50% | 3927/4931 |
| 近一年 | -19.59% | 3925/4400 |
| 近两年 | 12.19% | 2781/2954 |
| 近三年 | -9.77% | 2031/2253 |
| 成立以来 | -5.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.11% 4035/4961 |
-14.67% 4593/5312 |
- - |
- - |
| 2025 | 6.63% 2955/4813 |
-0.13% 2076/3635 |
5.04% 659/4076 |
4.89% 3642/4524 |
-3.09% 3248/4813 |
| 2024 | 2.63% 1966/3463 |
-4.68% 1740/2808 |
-8.31% 2213/3014 |
18.14% 1053/3129 |
-0.59% 1472/3463 |
| 2023 | -9.21% 1131/2656 |
3.23% 1234/2280 |
-5.99% 1576/2385 |
-3.78% 987/2515 |
-2.76% 525/2655 |
| 2022 | -18.77% 752/2207 |
-17.18% 1187/1919 |
6.07% 774/2016 |
-15.64% 1328/2113 |
9.61% 204/2208 |
| 2021 | -9.07% 1069/1822 |
-1.49% 503/1255 |
4.50% 879/1330 |
-15.24% 1383/1466 |
4.21% 355/1822 |
| 2020 | 27.16% 589/1250 |
-1.74% 233/1028 |
19.20% 309/1067 |
8.55% 707/1164 |
0.02% 1064/1184 |
| 2019 | 22.74% 641/1092 |
24.36% 514/754 |
-8.75% 608/804 |
1.66% 377/850 |
6.39% 613/918 |
| 2018 | -24.74% 330/834 |
- - |
- - |
- - |
-10.50% 198/691 |
| 2017 | 11.95% 287/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发养老指数C VS. 长安沪深300非周期A(740101) |